Insider Buying: Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Acquires $11,999,991.20 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the transaction, the insider now directly owns 795,411 shares in the company, valued at approximately $9,226,767.60. The trade was a -432.71 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $11.01 on Monday. Surrozen, Inc. has a 1 year low of $6.00 and a 1 year high of $18.17. The firm’s 50 day moving average price is $11.37 and its 200 day moving average price is $10.98.

Institutional Investors Weigh In On Surrozen

Hedge funds have recently made changes to their positions in the business. Regents of The University of California acquired a new position in Surrozen in the fourth quarter valued at $1,912,000. Stonepine Capital Management LLC increased its stake in shares of Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after acquiring an additional 27,200 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Surrozen during the 4th quarter worth about $688,000. Stempoint Capital LP boosted its position in shares of Surrozen by 91.7% in the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company’s stock worth $5,031,000 after acquiring an additional 167,655 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Surrozen by 26.1% in the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after purchasing an additional 4,630 shares during the period. Institutional investors and hedge funds own 66.57% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. HC Wainwright started coverage on Surrozen in a report on Thursday, January 30th. They issued a “buy” rating and a $32.00 price target for the company. Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Friday, January 3rd.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.